Trigeminal Neuralgia (TN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Trigeminal Neuralgia (TN) Market Outlook

Thelansis’s “Trigeminal Neuralgia (TN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Trigeminal Neuralgia (TN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Trigeminal Neuralgia (TN) Overview

Trigeminal neuralgia (TN), also known as tic douloureux, is a severe paroxysmal facial pain located within the trigeminal distribution on the face. This condition has been described as a “suicide disease” because of the extreme intensity of the pain. TN is one of several different types of facial pain that can have similar characteristics. Classic idiopathic trigeminal neuralgia is known as type I trigeminal neuralgia in the Burchiel classification. It is defined as episodic pain at least 50% of the time and located within any of the three divisions of the trigeminal nerve, commonly described as sharp, stabbing, or electrical shocklike in quality. The diagnosis is made solely on the basis of the history and the characteristic features of the pain. It occurs in paroxysms that last from a few seconds to several minutes. The frequency of outbreaks varies, ranging from hundreds of attacks per day to years-long remissions. The person is asymptomatic in between paroxysms. The pain is severe and described as intense, stabbing, superficial, sharp, or shooting, and often feels like an electric shock. It can be triggered by a light touch in any area innervated by the trigeminal nerve, such as when talking, washing the face, eating, or brushing the teeth. The condition can impair daily activities and cause depression pain.

• The incidence of Trigeminal neuralgia (TN) ranges from 12 to 16 cases per 100,000 population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: